The drug formulation market would grow at a CAGR of 6.05% over the predicted time frame. The market is expected to increase in value from US$ 1.64 Trn in 2022 to US$ 2.95 Trn in 2032.
The on drug formulation Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2561
A recent report provides crucial insights along with application based and forecast information in the Global Drug formulation Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Drug formulation market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Drug formulation market are included as given below:
Drug formulation Market Key Players
- Bristol-Myers Squibb
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- 3M Company
- Bayer AG
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- Sanofi SA
- GlaxoSmithKline plc
- Boston
Market Segments
By Formulation
- Tablets
- Capsules
- Injectable
- Sprays
- Suspensions
- Powders
- Other Formulations
By Routes of Administration
- Oral
- Topical
- Parenteral
- Inhalations
- Other Routes of Administration
By Therapy Area
- Cardiovascular Diseases (CVDs)
- Pain
- Diabetes
- Cancer
- Respiratory Diseases
- Other Diseases
By End-User
- Retail
- Non-retail
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Report Objectives
- To define, describe, and forecast the global drug formulation market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the drug formulation market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug Formulation Market
5.1. COVID-19 Landscape: Drug Formulation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug Formulation Market, By Formulation
8.1. Drug Formulation Market, by Formulation, 2023-2032
8.1.1. Tablets
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Capsules
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Injectable
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Sprays
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Suspensions
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Powders
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Other Formulations
8.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Drug Formulation Market, By Routes of Administration
9.1. Drug Formulation Market, by Routes of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Parenteral
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Inhalations
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Other Routes of Administration
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Drug Formulation Market, By Therapy Area
10.1. Drug Formulation Market, by Therapy Area, 2023-2032
10.1.1. Cardiovascular Diseases (CVDs)
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Pain
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Diabetes
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Cancer
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Respiratory Diseases
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Other Diseases
10.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Drug Formulation Market, By End-User
11.1. Drug Formulation Market, by End-User, 2023-2032
11.1.1. Retail
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Non-retail
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Drug Formulation Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.1.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.1.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.2.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.2.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.3.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.3.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.4.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.4.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.5.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Routes of Administration (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Therapy Area (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 13. Company Profiles
13.1. Bristol-Myers Squibb
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Gilead Sciences, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Merck & Co., Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Novartis AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AbbVie Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Boehringer Ingelheim International GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. F. Hoffmann-La Roche AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments